Key facts
- It has raised $13.8M; the latest was Early Stage VC in Sep 2025.
- Notable investors include GL Ventures, OrbiMed, Shenzhen Yifeng Investment Management Enterprise, Tianjin Venture Capital, Vinno Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Genocury
- ·The full record, as it builds
Funding rounds
No funding rounds for Genocury are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Genocury
Manufacturer of advanced biotechnology and life-science products aims to support precision diagnostics and therapeutic research. The company's offerings feature custom biomolecular reagents, diagnostic assay kits, and integrated lab service platforms, helping research institutions, pharmaceutical developers, and clinical labs achieve reliable experimental results and scalable testing workflows, enabling efficient translation of scientific discovery into real-world applications.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2021
- Website
- genocury.com/
- Ownership
- Privately Held (backing)
Genocury doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genocury shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genocury in its N-PORT filings yet. We sweep new filings monthly.